Impurities & Reference Standards

Cat. No.

A34465

CAS No.

2649400-33-7

(R,R)-Bexobrutideg

Synonyms: (R,R)-NX-5948; (R,R)-BTK-IN-24

(R,R)-Bexobrutideg is the (R,R)-enantiomer of Bexobrutideg, acting as a potent PROTAC that facilitates the targeted degradation of Bruton's tyrosine kinase (BTK) via the cereblon E3 ligase (CRBN) complex. This compound demonstrates significant anti-inflammatory effects by inhibiting B cell activation and has shown efficacy in tumor growth suppression in TMD8 xenograft models exhibiting wild-type BTK and BTKi resistance mutations. Additionally, (R,R)-Bexobrutideg is effective in a mouse model of collagen-induced arthritis and possesses the ability to penetrate the blood-brain barrier, making it a valuable tool for research into autoimmune diseases and hematological cancers.

Cat. No.

A40304

CAS No.

3031540-65-2

(Rac)-EBET-1055

(Rac)-EBET-1055 is a racemic mixture of the PROTAC degrader EBET-1055, targeting bromodomain and extra-terminal (BET) proteins. This compound effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC) while modulating the activity of cancer-associated fibroblasts (CAFs). Additionally, (Rac)-EBET-1055 enhances reporter gene activities in organoid co-cultures, making it a valuable tool for studying tumor microenvironment interactions and potential therapeutic strategies in cancer research.

Cat. No.

A65911

CAS No.

319-78-8

D-Isoleucine

Synonyms: (R)-Isoleucine

D-Isoleucine is a selective competitive activator of the Asc-1 antiporter, exhibiting a Ki value of 0.98 mM. By binding to the Asc-1 protein on neuronal cell membranes, D-Isoleucine facilitates the release of D-serine and glycine, thereby enhancing NMDA receptor-dependent synaptic plasticity. This compound is relevant in the study of neurodegenerative diseases, including Alzheimer's disease and schizophrenia. Additionally, D-Isoleucine serves as a non-classical D-amino acid, disrupting bacterial peptidoglycan synthesis and inhibiting biofilm formation in Staphylococcus aureus, suggesting its potential utility in antibacterial research.

Cat. No.

A66546

CAS No.

53108-00-2

(Rac)-Methylindazone

Synonyms: (Rac)-IAA-94

(Rac)-Methylindazone is the racemic mixture of Methylindazone, a potent blocker of the CLIC1 ion channel. This compound exhibits significant biological activity in modulating chloride ion transport, making it a valuable tool in research focused on ion channel function and related physiological processes. Potential applications include studies in cellular signaling and the investigation of CLIC1's role in various pathophysiological conditions.

Cat. No.

A74950

CAS No.

1191996-10-7

(S,S)-Sinogliatin

Synonyms: (S,S)-HMS-5552; (S,S)-RO-5305552

(S,S)-Sinogliatin is the (S,S)-enantiomer of the glucokinase activator Sinogliatin, specifically targeting glucokinase to enhance its activity. This compound demonstrates significant potential in the modulation of glucose metabolism, making it a valuable tool for research applications related to type 2 diabetes. Its use can aid in investigating the therapeutic mechanisms underlying glucose homeostasis and pancreatic function.

Cat. No.

A77249

CAS No.

3063345-48-9

(Rac)-LRK-4189

(Rac)-LRK-4189 is the racemic mixture of the selective PIP4K2C PROTAC degrader LRK-4189. This compound demonstrates potent biological activity with a DC50 of less than 500 nM for PIP4K2C in MOLT-4 cells, promoting antitumor effects by inducing intrinsic cell death and activating interferon signaling pathways. (Rac)-LRK-4189 is applicable in research focused on immune-mediated tumor cell killing, particularly in studies involving microsatellite stable (MSS) colorectal carcinoma.

Cat. No.

B19723

CAS No.

1145663-09-7

rel-Boc-Hyp-OMe

rel-Boc-Hyp-OMe is an isomer of Boc-Hyp-OMe, primarily serving as an experimental control in chemical research. It functions as a non-cleavable linker in the development of antibody-drug conjugates (ADCs), contributing to enhanced therapeutic efficacy. Additionally, it can be utilized as an alkyl chain-based linker in the synthesis of PROTACs for targeted protein degradation studies.